TY - JOUR T1 - Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only) JO - VALUE HEALTH PY - 2008/05/01 AU - Sofrygin O AU - Delea T AU - Tappenden P AU - Karnon J AU - Amonkar MM AU - Walker M ED - VL - 11 IS - 3 SP - A57 EP - A57 Y2 - 2025/05/20 ER -